FIBROGEN INC Contracts & Agreements

First Amended and Restated Evaluation Agreement by and between FibroGen, Inc. and Fortis Therapeutics, Inc., dated June 6, 2024 (Filed With SEC on August 6, 2024)

FibroGen, Inc. 2024 Equity Incentive Plan (Filed With SEC on June 7, 2024)

Amendment No. 1 to the Exclusive License and Option Agreement, between FibroGen, Inc. and HiFiBiO Inc., dated February 14, 2024 (Filed With SEC on May 6, 2024)

Termination and Transition Agreement to Development and Commercialization Agreement (for the U.S. and Certain Other Territories), by and between AstraZeneca AB and FibroGen, Inc.,... (Filed With SEC on May 6, 2024)

Non-Employee Director Compensation Policy, as amended, dated April 22, 2024 (Filed With SEC on May 6, 2024)

Offer Letter by and between FibroGen, Inc. and Deyaa Adib, M.D., dated February 6, 2024 (Filed With SEC on May 6, 2024)

FibroGen, Inc. Bonus Plan (Filed With SEC on February 26, 2024)

Amendment No. 1 to the Second Amended and Restated Exclusive License Agreement, dated as of November 16, 2023 (Filed With SEC on February 26, 2024)

Consulting Agreement, dated September 11, 2023, between FibroGen, Inc. and Mark Eisner (Filed With SEC on September 6, 2023)

Amended and Restated Exclusive License Agreement by and among FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd., and Eluminex Biosciences Suzhou) Limited,... (Filed With SEC on August 7, 2023)

Offer Letter, dated July 23, 2023, between FibroGen, Inc. and Thane Wettig (Filed With SEC on July 25, 2023)

Consulting Agreement, dated July 23, 2023, between FibroGen, Inc. and Enrique Conterno (Filed With SEC on July 25, 2023)

Amended and Restated Exclusive License Agreement by and between FibroGen, Inc. and Eluminex Biosciences (Suzhou) Limited as of January 21, 2022 (Filed With SEC on May 9, 2022)

Amendment No. 4 to Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd., and STA Pharmaceutical Hong Kong Limited, dated as of October... (Filed With SEC on February 28, 2022)

Transition Agreement by and between FibroGen, Inc. and Pat Cotroneo, dated as of August 14, 2021 (Filed With SEC on November 9, 2021)

Exclusive License Agreement by and between FibroGen, Inc. and Eluminex Biosciences (Suzhou) Limited as of July 16, 2021 (Filed With SEC on November 9, 2021)

Offer Letter by and between FibroGen, Inc. and Juan Graham, effective as of July 30, 2021 (Filed With SEC on November 9, 2021)

Sixth Amendment to the Lease by and between ARE-San Francisco No., 43, LLC and FibroGen, Inc. as of June 1, 2021 (Filed With SEC on August 9, 2021)

Exclusive License and Option Agreement by and between FibroGen, Inc. and HiFiBiO (HK) Limited (D.B.A. HiFiBiO Therapeutics), as of June 16, 2021 (Filed With SEC on August 9, 2021)

Transition, Separation, and Consulting Agreement by and between FibroGen, Inc. and K. Peony Yu, dated as of November 27, 2020 (Filed With SEC on May 10, 2021)

Astellas EU Supply Agreement by and between FibroGen, Inc. and Astellas Pharma Europe Ltd, effective as of January 1, 2021 (Filed With SEC on May 10, 2021)

Amendment No. 3 to Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd., and STA Pharmaceutical Hong Kong Limited, dated as of January... (Filed With SEC on May 10, 2021)

Master Services Agreement by and between FibroGen, Inc. and Samsung Biologics Co., Ltd., effective as of October 30, 2020 (Filed With SEC on March 1, 2021)

Product Specific Agreement by and between FibroGen, Inc. and Samsung Biologics Co., Ltd., effective as of October 30, 2020 (Filed With SEC on March 1, 2021)

Offer Letter, by and between FibroGen, Inc. and Mark Eisner, dated as of October 22, 2020 (Filed With SEC on March 1, 2021)

Collaboration Agreement by and between FibroGen, Inc. and Astellas Pharma Inc., effective June 1, 2005 (Filed With SEC on November 5, 2020)

Amendment No. 1 to Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd. and STA Pharmaceutical Hong Kong Limited, effective as of May... (Filed With SEC on August 6, 2020)

Amendment No. 1 to the Amended and Restated License, Development and Commercialization Agreement by and between FibroGen, Inc. and AstraZeneca AB, effective as of July 1, 2020 (Filed With SEC on August 6, 2020)

Second Amended and Restated License, Development and Commercialization Agreement by and among FibroGen China Anemia Holdings, Ltd., FibroGen China Medical Technology Development... (Filed With SEC on August 6, 2020)

Offer Letter, by and between FibroGen, Inc. and Thane Wettig, dated as of May 7, 2020 (Filed With SEC on August 6, 2020)

FibroGen, Inc. Non-Employee Director Compensation Policy, as amended (Filed With SEC on May 7, 2020)

Form of Executive Officer Change in Control and Severance Agreement (Filed With SEC on March 2, 2020)

Offer Letter, by and between FibroGen, Inc. and Enrique Conterno, dated as of December 17, 2019 (Filed With SEC on March 2, 2020)

Offer Letter, by and between FibroGen, Inc. and Elias Kouchakji, dated as of January 24, 2014 (Filed With SEC on March 2, 2020)

Offer Letter, by and between FibroGen, Inc. and Christine Chung, dated as of June 17, 2008 (Filed With SEC on March 2, 2020)

Commercial Supply Agreement by and between FibroGen, Inc. and Catalent Pharma Solutions, LLC, effective as of January 1, 2020 (Filed With SEC on March 2, 2020)

Description of Capital Stock of FibroGen, Inc (Filed With SEC on March 2, 2020)

Offer Letter, by and between FibroGen, Inc. and James Schoeneck, dated September 18, 2019 (Filed With SEC on November 12, 2019)

FibroGen, Inc. Non-Employee Director Compensation Policy, as amended (Filed With SEC on November 12, 2019)

FibroGen, Inc. Non-Employee Director Compensation Policy, as amended (Filed With SEC on August 8, 2019)

Amendment No. 33 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of January... (Filed With SEC on May 9, 2019)

Amendment No. 1 to Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of January 1, 2013 (Filed With SEC on February 27, 2019)

FibroGen, Inc. Non-Employee Director Compensation Policy, as amended (Filed With SEC on August 7, 2018)

Materials Transfer Agreement Letter to Astellas Pharma Inc., dated June 15, 2018 (Filed With SEC on August 7, 2018)

Preapproval Transfer Price Letter to Astellas Pharma Inc., dated June 15, 2018 (Filed With SEC on August 7, 2018)

Amendment No. 32 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of... (Filed With SEC on February 27, 2018)

Work Order No. 1 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of... (Filed With SEC on February 27, 2018)

Bonus Plan, adopted February 13, 2018 (Filed With SEC on February 16, 2018)

Shareholders Agreement by and among FibroGen International (Cayman) Limited and certain of its shareholders, dated as of September 8, 2017 (Filed With SEC on November 8, 2017)

Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of June 1, 2005 (Filed With SEC on November 8, 2017)

FibroGen,Inc. Common Stock, par value $0.01 per share Underwriting Agreement (Filed With SEC on August 16, 2017)

FIBROGEN, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT (Filed With SEC on May 9, 2017)

State-Owned Construction Land Use Right Granting Contract Promulgated by Ministry of Land and Resources of the Peoples Republic of China State Administration for Industry and... (Filed With SEC on May 9, 2017)

Amendment No. 31 to the Process Development and Clinical Supply Agreement (Filed With SEC on May 9, 2017)

FibroGen,Inc. Common Stock, par value $0.01 per share Underwriting Agreement (Filed With SEC on April 6, 2017)

Amendment No. 30 to the Process Development and Clinical Supply Agreement (Filed With SEC on March 1, 2017)

Amendment No. 29 to the Process Development and Clinical Supply Agreement (Filed With SEC on March 1, 2017)

Exhibit A Work Scope [*] (Version of June 8, 2016) [*] (Filed With SEC on November 8, 2016)

Exhibit A Work Scope [*] (Version of August 31, 2016) [*] (Filed With SEC on November 8, 2016)

Amendment No. 26 to the Process Development and Clinical Supply Agreement (Filed With SEC on August 8, 2016)

Amendment No. 25 to the Process Development and Clinical Supply Agreement (Filed With SEC on August 8, 2016)

Amendment No. 24 to the Process Development and Clinical Supply Agreement (Filed With SEC on August 8, 2016)

Amendment No. 22 to the Process Development and Clinical Supply Agreement (Filed With SEC on August 8, 2016)

FIBROGEN INCENTIVECOMPENSATION PLAN (Filed With SEC on June 10, 2016)

FibroGen, Inc. Non-Employee Director Compensation Policy Adopted: September 17, 2014 Amended: March 4, 2015 Amended: February 23, 2016, Effective as of the 2016 Annual Meeting of... (Filed With SEC on May 9, 2016)

AMENDMENT NO. 15 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on November 12, 2015)

AMENDMENT NO. 16 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on November 12, 2015)

AMENDMENT NO.17 TOTHE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on November 12, 2015)

Page 1 / 3 (Filed With SEC on November 12, 2015)

AMENDMENT NO.19 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on November 12, 2015)

AMENDMENT NO. 20 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on November 12, 2015)

AMENDMENT NO. 21 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on November 12, 2015)

AMENDMENT NO. 23 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on November 12, 2015)

FibroGen, Inc. Non-Employee Director Compensation Policy Adopted: September 17, 2014 Amended: March 4, 2015 Effective as of: The effective date of the initial public offering (Filed With SEC on March 26, 2015)

AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (for the US and Certain Other Territories) between FIBROGEN, INC. and ASTRAZENECA AB (Filed With SEC on November 12, 2014)

FibroGen, Inc. CommonStock, par value $0.01 per share Underwriting Agreement (Filed With SEC on November 12, 2014)

FIBROGEN, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:SEPTEMBER 09, 2014 APPROVED BY THE STOCKHOLDERS:SEPTEMBER 30, 2014 IPO DATE/EFFECTIVE DATE:[ ], 2014 (Filed With SEC on November 12, 2014)

FIBROGEN, INC. 2014EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THEBOARD OF DIRECTORS: SEPTEMBER 09, 2014 APPROVEDBY THE STOCKHOLDERS: SEPTEMBER 30, 2014 (Filed With SEC on November 12, 2014)

FIBROGEN 2014 INCENTIVECOMPENSATION PLAN (Filed With SEC on October 30, 2014)

FIBROGEN, INC. 2014EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THEBOARD OF DIRECTORS: SEPTEMBER 09, 2014 APPROVEDBY THE STOCKHOLDERS: SEPTEMBER 30, 2014 (Filed With SEC on October 24, 2014)

FIBROGEN, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:SEPTEMBER 09, 2014 APPROVED BY THE STOCKHOLDERS:SEPTEMBER 30, 2014 IPO DATE/EFFECTIVE DATE:[ ], 2014 (Filed With SEC on October 24, 2014)

COMMON STOCK PURCHASEAGREEMENT (Filed With SEC on October 24, 2014)

FIBROGEN, INC. CHANGEIN CONTROL AND SEVERANCE AGREEMENT (Filed With SEC on October 24, 2014)

INDEMNITY AGREEMENT (Filed With SEC on October 23, 2014)

AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (CHINA) between FIBROGEN CHINA ANEMIA HOLDINGS, LTD.; BEIJING FIBROGEN MEDICAL TECHNOLOGY DEVELOPMENT... (Filed With SEC on October 23, 2014)

FibroGen, Inc. Non-Employee Director Compensation Policy Adopted: September 17, 2014 Effective as of: The effective date of the initial public offering (Filed With SEC on October 23, 2014)

AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (for the US and Certain Other Territories) between FIBROGEN, INC. and ASTRAZENECA AB (Filed With SEC on October 20, 2014)

INVESTORS RIGHTS AGREEMENT (Filed With SEC on October 1, 2014)

INVESTOR RIGHTS AGREEMENT (Filed With SEC on October 1, 2014)

Category

Industry

Companies

Contracts

FIBROGEN INC Contracts & Agreements